Mechanism-based inhibitors of glycosidases: Design and applications

Advances in Carbohydrate Chemistry and Biochemistry

Volumn 71, Issue , 2014, Pages 297-338

  Kallemeijn, Wouter W ^a   Witte, Martin D ^b   Wennekes, Tom ^c   Aerts, Johannes M F G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Acid base; Activity based probes; Cyclophellitol; Cyclophellitol aziridine; Diagnostics; Enzyme replacement therapy; Epoxide; Fluorescent; Fluoroglycosides; Gaucher; GBA; Glucocerebrosidase; Glycosidases; Nucleophile; Retaining; Glucosidase

Indexed keywords

AZIRIDINE DERIVATIVE; BETA GLUCOSIDASE; CYCLOPHELLITOL; EPOXIDE; GLUCOSYLCERAMIDASE; GLYCOCONJUGATE; GLYCOSIDASE; GLYCOSIDASE INHIBITOR; GLYCOSIDE; GLYCOSYLCERAMIDASE;

ARTICLE; CARBOHYDRATE ANALYSIS; CATALYSIS; CATALYST; CELL LYSATE; CHEMICAL BOND; DRUG DESIGN; DRUG DEVELOPMENT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME SPECIFICITY; ENZYME STRUCTURE; GAUCHER DISEASE; GLYCOSYLATION AND DEGLYCOSYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROLOGICAL COMPLICATION; NONHUMAN; PROTEIN EXPRESSION; PROTON TRANSPORT; ANIMAL; BINDING SITE; CHEMISTRY; CONFORMATION; ENZYME ACTIVE SITE; HYDROLYSIS; MOUSE; MUTATION;

ANIMALS; BETA-GLUCOSIDASE; BINDING SITES; CATALYSIS; CATALYTIC DOMAIN; DRUG DESIGN; EPOXY COMPOUNDS; GLYCOSIDE HYDROLASES; HUMANS; HYDROLYSIS; LACTASE-PHLORIZIN HYDROLASE; MICE; MOLECULAR CONFORMATION; MUTATION;

EID: 84918794113     PISSN: 00652318     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800128-8.00004-2     Document Type: Chapter

References (274)

1. Laine R.A. A calculation of all possible oligosaccharide isomers both branched and linear yields 1.05 x 10(12) structures for a reducing hexasaccharide: The Isomer Barrier to development of single-method saccharide sequencing or synthesis systems. Glycobiology 1994, 4:759-767.
2. Moremen K.W., Tiemeyer M., Nairn A.V. Vertebrate protein glycosylation: Diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 2012, 13:448-462.
3. Cummings R.D. The repertoire of glycan determinants in the human glycome. Mol. Biosyst. 2009, 5:1087-1104.
4. Nairn A.V., Moremen K.W. Glycotranscriptomics. Handbook of Glycomics 2009, 81-136. Academic Press/Elsevier, (http://www.sciencedirect.com/science/book/9780123736000). J.M. Pierce, R.D. Cummings (Eds.).
5. Nairn A.V., York W.S., Harris K., Hall E.M., Pierce J.M., Moremen K.W. Regulation of glycan structures in animal tissues: Transcript profiling of glycan-related genes. J. Biol. Chem. 2008, 283:17298-17313.
6. Spiro R.G. Protein glycosylation: Nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002, 12:43R-56R.
7. Davies G.J., Gloster T.M., Henrissat B. Recent structural insights into the expanding world of carbohydrate-active enzymes. Curr. Opin. Struct. Biol. 2005, 15:637-645.
8. Cantarel B.L., Coutinho P.M., Rancurel C., Bernard T., Lombard V., Henrissat B. The Carbohydrate-Active EnZymes database (CAZy): An expert resource for glycogenomics. Nucleic Acids Res. 2009, 37:D233-D238.
9. Wolfenden R., Ridgway C., Young G. Spontaneous hydrolysis of glycosides. J. Am. Chem. Soc. 1998, 120:833-834.
10. Carmi N., Breaker R.R. Characterization of a DNA-cleaving deoxyribozyme. Bioorg. Med. Chem. 2001, 9:2589-2600.
11. Breaker R.R. Catalytic DNA: In training and seeking employment. Nat. Biotechnol. 1999, 17:422-423.
12. Li Y., Breaker R.R. Kinetics of RNA degradation by specific base catalysis of transesterification involving the 2'-hydroxyl group. J. Am. Chem. Soc. 1999, 121:5364-5372.
13. Wolfenden R.R., Lu X., Young G. Spontaneous hydrolysis of glycosides. J. Am. Chem. Soc. 1998, 120:6814-6815.
14. Naumoff D.G. Hierarchical classification of glycoside hydrolases. Biochemistry (Mosc) 2011, 76:622-635.
15. Henrissat B. A classification of glycosyl hydrolases based on amino-acid-sequence similarities. Biochem. J. 1991, 280:309-316.
16. Henrissat B., Bairoch A. New families in the classification of glycosyl hydrolases based on amino-acid-sequence similarities. Biochem. J. 1993, 293:781-788.
17. Davies G.J., Sinnott M.L. Sorting the diverse: The sequence-based classifications of carbohydrate-active enzymes. Biochem. J. 2008, 1-5. 10.1042/B J20080382.
18. Roseman S. Reflections on glycobiology. J. Biol. Chem. 2001, 276:41527-41542.
19. Asano N., Nash R.J., Molyneux R.J., Fleet G.W.J. Sugar-mimic glycosidase inhibitors: Natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron Asymmetry 2000, 11:1645-1680.
20. Asano N. Glycosidase inhibitors: Update and perspectives on practical use. Glycobiology 2003, 13:93R-104R.
21. de Melo E.B., Gomes A.D., Carvalho I. α- and β-glucosidase inhibitors: Chemical structure and biological activity. Tetrahedron 2006, 62:10277-10302.
22. Alper J. Glycobiology. Turning sweet on cancer. Science 2003, 301:159-160.
23. Tiwari V.K., Mishra R.C., Sharma A., Tripathi R.P. Carbohydrate based potential chemotherapeutic agents: Recent developments and their scope in future drug discovery. Mini Rev. Med. Chem. 2012, 12:1497-1519.
24. Humphries M.J., Matsumoto K., White S.L., Olden K. Oligosaccharide modification by swainsonine treatment inhibits pulmonary colonization by B16-F10 murine melanoma cells. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:1752-1756.
25. Robina I., Moreno-Vargas A.J., Carmona A.T., Vogel P. Glycosidase inhibitors as potential HIV entry inhibitors?. Curr. Drug Metab. 2004, 5:329-361.
26. Chairat K., Tarning J., White N.J., Lindegardh N. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J. Clin. Pharmacol. 2013, 53:119-139.
27. Block T.M., Lu X., Platt F.M., Foster G.R., Gerlich W.H., Blumberg B.S., Dwek R.A. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:2235-2239.
28. Nietupski J.B., Pacheco J.J., Chuang W.L., Maratea K., Li L., Foley J., Ashe K.M., Cooper C.G., Aerts J.M., Copeland D.P., Scheule R.K., Cheng S.H., Marshall J. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol. Genet. Metab. 2012, 105:621-628.
29. Ashe K.M., Bangari D., Li L., Cabrera-Salazar M.A., Bercury S.D., Nietupski J.B., Cooper C.G., Aerts J.M., Lee E.R., Copeland D.P., Cheng S.H., Scheule R.K., Marshall J. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLoS One 2011, 6:e21758.
30. Yuzwa S.A., Shan X., Macauley M.S., Clark T., Skorobogatko Y., Vosseller K., Vocadlo D.J. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 2012, 8:393-399.
31. Lombardo E., van Roomen C.P.A.A., van Puijvelde G.H., Ottenhoff R., van Eijk M., Aten J., Kuiper J., Overkleeft H.S., Groen A.K., Verhoeven A.J., Aerts J.M., Bietrix F. Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism. PLoS One 2012, 7:e38520.
32. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:931-937.
33. Bijl N., Sokolovic M., Vrins C., Langeveld M., Moerland P.D., Ottenhoff R., van Roomen C.P.A.A., Claessen N., Boot R.G., Aten J., Groen A.K., Aerts J.M., van Eijk M. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 2009, 50:1431-1441.
34. Venier R.E., Igdoura S.A. Miglustat as a therapeutic agent: Prospects and caveats. J. Med. Genet. 2012, 49:591-597.
35. Benito J.M., García Fernández J.M., Ortiz-Mellet C. Pharmacological chaperone therapy for Gaucher disease: A patent review. Expert Opin. Ther. Pat. 2011, 21:885-903.
36. Radin N.S. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J. 1996, 13:153-157.
37. Aerts J.M., Hollak C.E., Boot R.G., Groener J.E., Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J. Inherit. Metab. Dis. 2006, 29:449-456.
38. Koshland D.E. Stereochemistry and mechanism of enzymatic reactions. Biol. Rev. Camb. Philos. Soc. 1953, 28:416-436.
39. McCarter J.D., Withers S.G. Mechanisms of enzymatic glycoside hydrolysis. Curr. Opin. Struct. Biol. 1994, 4:885-892.
40. Zechel D.L., Withers S.G. Glycosidase mechanisms: Anatomy of a finely tuned catalyst. Acc. Chem. Res. 2000, 33:11-18.
41. Sinnott M.L. Catalytic mechanisms of enzymatic glycosyl transfer. Chem. Rev. 1990, 90:1171-1202.
42. Vasella A., Davies G.J., Bohm M. Glycosidase mechanisms. Curr. Opin. Chem. Biol. 2002, 6:619-629.
43. Yip V.L., Withers S.G. Nature's many mechanisms for the degradation of oligosaccharides. Org. Biomol. Chem. 2004, 2:2707-2713.
44. Rye C.S., Withers S.G. Glycosidase mechanisms. Curr. Opin. Chem. Biol. 2000, 4:573-580.
45. Lai E.C., Morris S.A., Street I.P., Withers S.G. Substituted glycals as probes of glycosidase mechanisms. Bioorg. Med. Chem. 1996, 4:1929-1937.
46. Sidhu G., Withers S.G., Nguyen N.T., McIntosh L.P., Ziser L., Brayer G.D. Sugar ring distortion in the glycosyl-enzyme intermediate of a family GH11 xylanase. Biochemistry 1999, 38:5346-5354.
47. Sabini E., Sulzenbacker G., Dauter M., Dauter Z., Jorgensen P.L., Schulein M., Dupont C., Davies G.J., Wilson K.S. Catalysis and specificity in enzymatic glycoside hydrolysis: A 2,5B conformation for the glycosyl-enzyme intermediate revealed by the structure of the Bacillus agaradhaerens family 11 xylanase. Chem. Biol. 1999, 6:483-492.
48. Davies G.J., Ducros V.M., Varrot A., Zechel D.L. Mapping the conformational itinerary of β-glycosidases by X-ray crystallography. Biochem. Soc. Trans. 2003, 31:523-527.
49. Gloster T.M., Roberts S., Ducros V.M., Perugino G., Rossi M., Hoos R., Moracci M., Vasella A., Davies G.J. Structural studies of the β-glycosidase from Sulfolobus solfataricus in complex with covalently and noncovalently bound inhibitors. Biochemistry 2004, 43:6101-6109.
50. Lawson S.L., Wakarchuk W.W., Withers S.G. Positioning the acid/base catalyst in a glycosidase: Studies with Bacillus circulans xylanase. Biochemistry 1997, 36:2257-2265.
51. Mark B.L., Vocadlo D.J., Knapp S., Triggs-Raine B.L., Withers S.G., James M.N. Crystallographic evidence for substrate-assisted catalysis in a bacterial β-hexosaminidase. J. Biol. Chem. 2001, 276:10330-10337.
52. Piszkiewicz D., Bruice T.C. Glycoside hydrolysis. II. Intramolecular carboxyl and acetamido group catalysis in β-glycoside hydrolysis. J. Am. Chem. Soc. 1968, 90:2156-2163.
53. Macauley M.S., Whitworth G.E., Debowski A.W., Chin D., Vocadlo D.J. O-GlcNAcase uses substrate-assisted catalysis-Kinetic analysis and development of highly selective mechanism-inspired inhibitors. J. Biol. Chem. 2005, 280:25313-25322.
54. Terwisscha van Scheltinga A.C., Armand S., Kalk K.H., Isogai A., Henrissat B., Dijkstra B.W. Stereochemistry of chitin hydrolysis by a plant chitinase/lysozyme and X-ray structure of a complex with allosamidin: Evidence for substrate assisted catalysis. Biochemistry 1995, 34:15619-15623.
55. Knapp S., Vocadlo D., Gao Z., Kirk B., Lou J., Withers S.G. NAGthiazoline, an N-acetyl-β-hexosaminidase inhibitor that implicates acetamido participation. J. Am. Chem. Soc. 1996, 118:6804-6805.
56. Vocadlo D.J., Withers S.G. Detailed comparative analysis of the catalytic mechanisms of β-acetyl-glucosaminidases from families 3 and 20 of glycoside hydrolases. Biochemistry 2005, 44:12809-12818.
57. Drouillard S., Armand S., Davies G.J., Vorgias C.E., Henrissat B. Serratia marcescens chitobiase is a retaining glycosidase utilizing substrate acetamido group participation. Biochem. J. 1997, 328:945-949.
58. Amaya M.F., Watts A.G., Damager I., Wehenkel A., Nguyen T., Buschiazzo A., Paris G., Frasch A.C., Withers S.G., Alzari P.M. Structural insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase. Structure 2004, 12:775-784.
59. Watts A.G., Damager I., Amaya M.L., Buschiazzo A., Alzari P., Frasch A.C., Withers S.G. Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: Tyrosine is the catalytic nucleophile. J. Am. Chem. Soc. 2003, 125:7532-7533.
60. Watson J.N., Dookhun V., Borgford T.J., Bennet A.J. Mutagenesis of the conserved active-site tyrosine changes a retaining sialidase into an inverting sialidase. Biochemistry 2003, 42:12682-12690.
61. Yip V.L., Withers S.G. Breakdown of oligosaccharides by the process of elimination. Curr. Opin. Chem. Biol. 2006, 10:147-155.
62. Burmeister W.P., Cottaz-Rollin P., Vasella A., Henrissat B. High resolution X-ray crystallography shows that ascorbate is a cofactor for myrosinase and substitutes for the function of the catalytic base. J. Biol. Chem. 2000, 275:39385-39393.
63. Hehre E.J. Glycosyl transfer: A history of the concept's development and view of its major contributions to biochemistry. Carbohydr. Res. 2001, 331:347-368.
64. Hehre E.J. A fresh understanding of the stereochemical behavior of glycosylases: Structural distinction of "inverting" (2-MCO-type) versus "retaining" (1-MCO type) enzymes. Adv. Carbohydr. Chem. Biochem. 1999, 55:265-310.
65. Fan J.Q. A contradictory treatment for lysosomal storage disorders: Inhibitors enhance mutant enzyme activity. Trends Pharmacol. Sci. 2003, 24:355-360.
66. Brooks D.A. Getting into the fold. Nat. Chem. Biol. 2007, 3:84-85.
67. Boyd R.E., Lee G., Rybczynski P., Benjamin E.R., Khanna R., Wustman B.A., Valenzano K.J. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J. Med. Chem. 2013, 56:2705-2725.
68. Benito J.M., García Fernández J.M., Ortiz Mellet C. Pharmacological chaperone therapy for Gaucher disease: A patent review. Expert Opin. Ther. Pat. 2011, 21:885-903.
69. Witte M.D., van der Marel G.A., Aerts J.M., Overkleeft H.S. Irreversible inhibitors and activity-based probes as research tools in chemical glycobiology. Org. Biomol. Chem. 2011, 9:5908-5926.
70. Sadaghiani A.M., Verhelst S.H., Bogyo M. Tagging and detection strategies for activity-based proteomics. Curr. Opin. Chem. Biol. 2007, 11:20-28.
71. Shi W., Ma H. Spectroscopic probes with changeable π-conjugated systems. Chem. Commun. (Camb.) 2012, 48:8732-8744.
72. Treibs A., Kreuzer F.H. Difluorboryl-komplexe von di- und tripyrrylmethenen. Justus Liebigs Ann. Chem. 1968, 718:208-223.
73. Schmitt A., Hinkeldey B., Wild M., Jung G. Synthesis of the core compound of the BODIPY dye class: 4,4'-Difluoro-4-bora-(3a,4a)-diaza-s-indacene. J. Fluoresc. 2009, 19:755-759.
74. Tram K., Yan H., Jenkins H.A., Vassiliev S., Bruce D. The synthesis and crystal structure of unsubstituted 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY). Dyes Pigments 2009, 82:392-395.
75. Arroyo I.J., Hu R., Merino G., Tang B.Z., Peña-Cabrera E. The smallest and one of the brightest. Efficient preparation and optical description of the parent borondipyrromethene system. J. Org. Chem. 2009, 74:5719-5722.
76. Loudet A., Burgess K. BODIPY dyes and their derivatives: Syntheses and spectroscopic properties. Chem. Rev. 2007, 107:4891-4932.
77. Lopatin D.E., Voss E.W. Fluorescein. Hapten and antibody active-site probe. Biochemistry 1971, 10:208-213.
78. Ohkuma S., Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:3327-3331.
79. Best Q.A., Sattenapally N., Dyer D.J., Scott C.N., McCarroll M.E. pH-dependent Si-fluorescein hypochlorous acid fluorescent probe: Spirocycle ring-opening and excess hypochlorous acid-induced chlorination. J. Am. Chem. Soc. 2013, 135:13365-13370.
80. Huang R., Wang X., Wang D., Liu F., Mei B., Tang A., Jiang J., Liang G. Multifunctional fluorescent probe for sequential detections of glutathione and caspase-3 in vitro and in cells. Anal. Chem. 2013, 85:6203-6207.
81. Arbeloa I.L., Ojeda P.R. Molecular forms of rhodamine B. Chem. Phys. Lett. 1981, 79:347-350.
82. Walsh R.J., Reinot T., Hayes J.M., Kalli K.R., Hartmann L.C., Small G.J. Nonphotochemical hole burning spectroscopy of a mitochondrial selective rhodamine dye molecule in normal and cancerous ovarian surface epithelial cells. J. Lumin. 2002, 98:115-121.
83. Abugo O.O., Nair R., Lakowicz J.R. Fluorescence properties of rhodamine 800 in whole blood and plasma. Anal. Biochem. 2000, 279:142-150.
84. Miller A.K., Tausig F. Biotin-binding by parenterally-administered streptavidin or avidin. Biochem. Biophys. Res. Commun. 1964, 14:210-214.
85. Hofmann K., Wood S.W., Brinton C.C., Montibeller J.A., Finn F.M. Iminobiotin affinity columns and their application to retrieval of streptavidin. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:4666-4668.
86. Tsai C.S., Yen H.Y., Lin M.I., Tsai T.I., Wang S.Y., Huang W.I., Hsu T.L., Cheng Y.S., Fang J.M., Wong C.H. Cell-permeable probe for identification and imaging of sialidases. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2466-2471.
87. Vocadlo D.J., Hang H.C., Kim E.J., Hanover J.A., Bertozzi C.R. A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9116-9121.
88. Martin D.D., Vilas G.L., Prescher J.A., Rajaiah G., Falck J.R., Bertozzi C.R., Berthiaume L.G. Rapid detection, discovery, and identification of post-translationally myristoylated proteins during apoptosis using a bio-orthogonal azidomyristate analog. FASEB J 2008, 22:797-806.
89. Kele P., Li X., Link M., Nagy K., Herner A., Lorincz K., Beni S., Wolfbeis O.S. Clickable fluorophores for biological labeling-With or without copper. Org. Biomol. Chem. 2009, 7:3486-3490.
90. Willems L.I., Li N., Florea B.I., Ruben M., van der Marel G.A., Overkleeft H.S. Triple bio-orthogonal ligation strategy for simultaneous labeling of multiple enzymatic activities. Angew. Chem. Int. Ed. Engl. 2012, 51:4431-4434.
91. Willems L.I., van der Linden W.A., Li N., Li K.-Y., Liu N., Hoogendoorn S., van der Marel G.A., Florea B.I., Overkleeft H.S. Bioorthogonal chemistry: Applications in activity-based protein profiling. Acc. Chem. Res. 2011, 44:718-729.
92. Roeser K.R., Legler G. Role of sugar hydroxyl groups in glycoside hydrolysis. Cleavage mechanism of deoxyglucosides and related substrates by β-glucosidase A3 from Aspergillus wentii. Biochim. Biophys. Acta 1981, 657:321-333.
93. McCarter J., Adam M., Withers S.G. Binding energy and catalysis: Fluorinated and deoxygenated glycosides as mechanistic probes of Escherichia coli (lacZ) β-galactosidase. Biochem. J. 1992, 286:721-727.
94. Legler G. Glycoside hydrolases: Mechanistic information from studies with reversible and irreversible inhibitors. Adv. Carbohydr. Chem. Biochem. 1990, 48:319-384.
95. Withers S.G., Street I.P., Bird P., Dolphin D.H. 2-Deoxy-2-fluoro-glucosides: A novel class of mechanism-based glucosidase inhibitors. J. Am. Chem. Soc. 1987, 109:7530-7531.
96. Withers S.G., Rupitz K., Street I.P. 2-Deoxy-2-fluoro-d-glycosyl fluorides. A new class of specific mechanism-based glycosidase inhibitors. J. Biol. Chem. 1988, 263:7929-7932.
97. Street I.P., Rupitz K., Withers S.G. Fluorinated and deoxygenated substrates as probes of transition state structure in glycogen phosphorylase. Biochemistry 1989, 28:1581-1587.
98. Street I.P., Kempton J.B., Withers S.G. Inactivation of a β-glucosidase through the accumulation of a stable 2-deoxy-2-fluoro-α-d-glucopyranosyl-enzyme intermediate: A detailed investigation. Biochemistry 1992, 31:9970-9978.
99. Cottaz S., Henrissat B., Driguez H. Mechanism-based inhibition and stereochemistry of glucosinolate hydrolysis by myrosinase. Biochemistry 1996, 35:15256-15259.
100. McCarter J.D., Yeung W., Chow J., Dolphin D., Withers S.G. Design and synthesis of 2'-deoxy-2'-fluorodisaccharides as mechanism-based glycosidase inhibitors that exploit aglycone specificity. J. Am. Chem. Soc. 1997, 119:5792-5797.
101. Braun C., Brayer G.D., Withers S.G. Mechanism-based inhibition of yeast α-glucosidase and human pancreatic α-amylase by a new class of inhibitors-2-Deoxy-2,2-difluoro-α-glycosides. J. Biol. Chem. 1995, 270:26778-26781.
102. McCarter J.D., Withers S.G. Unequivocal identification of Asp-214 as the catalytic nucleophile of Saccharomyces cerevisiae α-glucosidase using 5-fluoro glycosyl fluorides. J. Biol. Chem. 1996, 271:6889-6894.
103. Kajimoto T., Liu K.K.C., Pederson R.L., Zhong Z., Ichikawa Y., Porco J.A., Wong C.H. Enzyme-catalyzed aldol condensation for asymmetric synthesis of azasugars: Synthesis, evaluation, and modeling of glycosidase inhibitors. J. Am. Chem. Soc. 1991, 113:6187-6196.
104. White A., Tull D., Johns K., Withers S.G., Rose D.R. Crystallographic observation of a covalent catalytic intermediate in a β-glycosidase. Nat. Struct. Biol. 1996, 3:149-154.
105. Notenboom V., Birsan C., Nitz M., Rose D.R., Warren R.A., Withers S.G. Insights into transition state stabilization of the β-1,4-glycosidase Cex by covalent intermediate accumulation in active site mutants. Nat. Struct. Biol. 1998, 5:812-818.
106. Shaikh F.A., Müllegger J., He S., Withers S.G. Identification of the catalytic nucleophile in family 42 β-galactosidases by intermediate trapping and peptide mapping: YesZ from Bacillus subtilis. FEBS Lett. 2007, 581:2441-2446.
107. Tarling C.A., He S., Sulzenbacher G., Bignon C., Bourne Y., Henrissat B., Withers S.G. Identification of the catalytic nucleophile of the family 29 α-l-fucosidase from Thermotoga maritima through trapping of a covalent glycosyl-enzyme intermediate and mutagenesis. J. Biol. Chem. 2003, 278:47394-47399.
108. Withers S.G., Aebersold R. Approaches to labeling and identification of active-site residues in glycosidases. Protein Sci. 1995, 4:361-372.
109. Withers S.G., Street I.P. Identification of a covalent α-d-glucopyranosyl enzyme intermediate formed on a β-glucosidase. J. Am. Chem. Soc. 1988, 110:8551-8553.
110. Tull D., Burgoyne D.L., Chow D.T., Withers S.G., Aebersold R. A mass spectrometry-based approach for probing enzyme active sites: Identification of Glu 127 in Cellulomonas fimi exoglycanase as the residue modified by N-bromoacetyl cellobiosylamine. Anal. Biochem. 1996, 234:119-125.
111. Michikawa M., Ichinose H., Momma M., Biely P., Jongkees S., Yoshida M., Kotake T., Tsumuraya Y., Withers S.G., Fujimoto Z., Kaneko S. Structural and biochemical characterization of glycoside hydrolase family 79 β-glucuronidase from Acidobacterium capsulatum. J. Biol. Chem. 2012, 287:14069-14077.
112. Gebler J.C., Aebersold R., Withers S.G. Glu-537, not Glu-461, is the nucleophile in the active site of (lacZ) β-galactosidase from Escherichia coli. J. Biol. Chem. 1992, 267:11126-11130.
113. Wang Q., Tull D., Meinke A., Gilkes N.R., Warren R.A., Aebersold R., Withers S.G. Glu-280 is the nucleophile in the active site of Clostridium thermocellum Cel C, a Family A endoglucanase. J. Biol. Chem. 1993, 268:14096-14103.
114. Miao S., McCarter J.D., Grace M.E., Grabowski G.A., Aebersold R., Withers S.G. Identification of Glu 340 as the active site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry. J. Biol. Chem. 1994, 269:10975-10978.
115. Miao S., Ziser L., Aebersold R., Withers S.G. Identification of glutamic acid 78 as the active site nucleophile in Bacillus subtilis xylanase using electrospray tandem mass spectrometry. Biochemistry 1994, 33:7027-7032.
116. Withers S.G., Warren R.A.J., Street I.P., Rupitz K., Kempton J.B., Aebersold R. Unequivocal demonstration of the involvement of a glutamate residue as a nucleophile in the mechanism of a retaining glycosidase. J. Am. Chem. Soc. 1990, 112:5887-5889.
117. Ly H.D., Howard S., Shum K., He S., Zhu A., Withers S.G. The synthesis, testing and use of 5-fluoro-α-d-galactosyl fluoride to trap an intermediate on green coffee bean α-galactosidase and identify the catalytic nucleophile. Carbohydr. Res. 2000, 329:539-547.
118. Vocadlo D.J., Mayer C., He S., Withers S.G. Mechanism of action and identification of Asp242 as the catalytic nucleophile of Vibrio furnisii N-acetyl-β-d-glucosaminidase using 2-acetamido-2-deoxy-5-fluoro-α-l-idopyranosyl fluoride. Biochemistry 2000, 39:117-126.
119. Zhang Y., Bommuswamy J., Sinnott M.L. Kinetic isotope effect study of transitions states for the hydrolysis of α- and β-glucopyranosyl fluorides. J. Am. Chem. Soc. 1994, 116:7557-7563.
120. N2) mechanism. J. Am. Chem. Soc. 1991, 113:7951-7958.
121. Ly H.D., Withers S.G. Mutagenesis of glycosidases. Annu. Rev. Biochem. 1999, 68:487-522.
122. Knegtel R.M., Strokopytov B., Penninga D., Faber O.G., Rozeboom H.J., Kalk K.H., Dijkhuizen L., Dijkstra B.W. Crystallographic studies of the interaction of cyclodextrin glycosyltransferase from Bacillus circulans strain-251 with natural substrates and products. J. Biol. Chem. 1995, 270:29256-29264.
123. Mosi R., He S., Uitdehaag J., Dijkstra B.W., Withers S.G. Trapping and characterization of the reaction intermediate in cyclodextrin glycosyltransferase by use of activated substrates and a mutant enzyme. Biochemistry 1997, 36:9927-9934.
124. McCarter J.D., Adam M.J., Hartman N.G., Withers S.G. In vivo inhibition of β-glucosidase and β-mannosidase activity in rats by 2-deoxy-2-fluoro-β-glycosyl fluorides and recovery of activity in vivo and in vitro. Biochem. J. 1994, 301:343-348.
125. Phenix C.P., Rempel B.P., Colobong K., Doudet D.J., Adam M.J., Clarke L.A., Withers S.G. Imaging of enzyme replacement therapy using PET. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10842-10847.
126. Zechel D.L., He S., Dupont C., Withers S.G. Identification of Glu-120 as the catalytic nucleophile in Streptomyces lividans endoglucanase celB. Biochem. J. 1998, 336:139-145.
127. Poon D.K., Ludwiczek M.L., Schubert M., Kwan E.M., Withers S.G., McIntosh L.P. NMR spectroscopic characterization of a beta-(1,4)-glycosidase along its reaction pathway: Stabilization upon formation of the glycosyl-enzyme intermediate. Biochemistry 2007, 46:1759-1770.
128. Hekmat O., Florizone C., Kim Y.W., Eltis L.D., Warren R.A., Withers S.G. Specificity fingerprinting of retaining beta-1,4-glycanases in the Cellulomonas fimi secretome using two fluorescent mechanism-based probes. Chembiochem 2007, 8:2125-2132.
129. Williams S.J., Hekmat O., Withers S.G. Synthesis and testing of mechanism-based protein-profiling probes for retaining endo-glycosidases. Chembiochem 2006, 7:116-124.
130. Vocadlo D.J., Bertozzi C.R. A strategy for functional proteomic analysis of glycosidase activity from cell lysates. Angew. Chem. Int. Ed. Engl. 2004, 43:5338-5342.
131. Stubbs K.A., Scaffidi A., Debowski A.W., Mark B.L., Stick R.V., Vocadlo D.J. Synthesis and use of mechanism-based protein-profiling probes for retaining beta-D-glucosaminidases facilitate identification of Pseudomonas aeruginosa NagZ. J. Am. Chem. Soc. 2008, 130:327-335.
132. Walvoort M.T., Kallemeijn W.W., Willems L.I., Witte M.D., Aerts J.M., van der Marel G.A., Codee J.D., Overkleeft H.S. Tuning the leaving group in 2-deoxy-2-fluoroglucoside results in improved activity-based retaining β-glucosidase probes. Chem. Commun. (Camb.) 2012, 48:10386-10388.
133. Legler G. Studies on the action mechanism of glycoside splitting enzymes. I. Presentation and properties of specific inhibitors. Hoppe-Seyler's Z. Physiol. Chem. 1966, 345:197-214.
134. 14C]Condurit-B-epoxid. Hoppe-Seyler's Z. Physiol. Chem. 1968, 349:767-774.
135. 3H]6-Brom-6-desoxy-condurit-B-epoxid. Hoppe-Seyler's Z. Physiol. Chem. 1975, 351:25-31.
136. Febbraio F., Barone R., D'Auria S., Rossi M., Nucci R., Piccialli P., De Napoli L., Orrù S., Pucci P. Identification of the active site nucleophile in the thermostable beta-glycosidase from the archaeon Sulfolobus solfataricus expressed in Escherichia coli. Biochemistry 1997, 36:3068-3075.
137. Quaroni A., Gershon-Quaroni E., Semenza G. Tryptic digestion of native small-intestinal sucrase-isomaltase complex: Isolation of the sucrase subunit. Eur. J. Biochem. 1975, 52:481-486.
138. Quaroni A., Semenza G. Partial amino-acid sequences around essential carboxylate in active-sites of intestinal sucrase-isomaltase complex. J. Biol. Chem. 1976, 251:3250-3253.
139. Quaroni A., Gershon E., Semenza G. Affinity labeling of active-sites in sucrase-isomaltase complex from small-intestine. J. Biol. Chem. 1974, 249:6424-6433.
140. Hermans M.M.P., Kroos M.A., van Beeumen J., Oostra B.A., Reuser A.J.J. Human lysosomal α-glucosidase-Characterization of the catalytic site. J. Biol. Chem. 1991, 266:13507-13512.
141. Iwanami S., Matsui H., Kimura A., Ito H., Mori H., Honma M., Chiba S. Chemical modification and amino-acid-sequence of active-site in sugar-beet α-glucosidase. Biosci. Biotechnol. Biochem. 1995, 59:459-463.
142. Kimura A., Takata M., Fukushi Y., Mori H., Matsui H., Chiba S. A catalytic amino acid and primary structure of active site in Aspergillus niger α-glucosidase. Biosci. Biotechnol. Biochem. 1997, 61:1091-1098.
143. Okuyama M., Okuno A., Shimizu N., Mori H., Kimura A., Chiba S. Carboxyl group of residue Asp647 as possible proton donor in catalytic reaction of α-glucosidase from Schizosaccharomyces pombe. Eur. J. Biochem. 2001, 268:2270-2280.
144. Braun H., Legler G., Deshusses J., Semenza G. Stereospecific ring opening of conduritol-B-epoxide by an active site aspartate residue of sucrase-isomaltase. Biochim. Biophys. Acta 1977, 483:135-140.
145. Yang S.J., Ge S.G., Zeng Y.C., Zhang S.Z. Inactivation of α-glucosidase by the active-site-directed inhibitor, conduritol B epoxide. Biochim. Biophys. Acta 1985, 828:236-240.
146. Lovering A.L., Lee S.S., Kim Y.W., Withers S.G., Strynadka N.C.J. Mechanistic and structural analysis of a family 31 α-glycosidase and its glycosyl-enzyme intermediate. J. Biol. Chem. 2005, 280:2105-2115.
147. Legler G. Labelling of the active centre of a β-glucosidase. Biochim. Biophys. Acta 1968, 151:728-729.
148. Mercier D., Olesker A., Gero S.D., Barnett J.E.G. The synthesis of 1l-1,2-anhydro-myo-inositol and 1l- and dl-1,2-anhydro-chiro-inositol. Carbohydr. Res. 1971, 18:227-231.
149. Braun H. External yeast β-fructosidase. Affinity labeling of the active site. Biochim. Biophys. Acta 1976, 452:452-457.
150. Cavanagh K.T., Fisher R.A., Legler G., Herrchen M., Jones M.Z., Julich E., Sewell Alger R.P., Sinnott M.L., Wilkinson F.E. Goat liver β-mannosidases: Molecular properties, inhibition and inactivation of the lysosomal and nonlysosomal forms. Enzyme 1985, 34:75-82.
151. Legler G., Herrchen M. Active site-directed inhibition of galactosidases by conduritol C epoxides (1,2-anhydro-epi- and neo-inositol). FEBS Lett. 1981, 135:139-144.
152. White W.J., Schray K.J., Legler G., Alhadeff J.A. Active-site-directed inactivation of human liver α-l-fucosidase by conduritol C trans-epoxide. Biochim. Biophys. Acta 1986, 873:198-203.
153. Herrchen M., Legler G. Identification of an essential carboxylate group at the active-site of lacZ β-galactosidase from Escherichia coli. Eur. J. Biochem. 1984, 138:527-531.
154. Dinur T., Osiecki K.M., Legler G., Gatt S., Desnick R.J., Grabowski G.A. Human acid β-glucosidase-Isolation and amino-acid-sequence of a peptide containing the catalytic site. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:1660-1664.
155. Legler G., Harder A. Amino-acid sequence at the active-site of β-glucosidase A from bitter almonds. Biochim. Biophys. Acta 1978, 524:102-108.
156. Withers S.G., Umezawa K. Cyclophellitol-A naturally-occurring mechanism-based inactivator of β-glucosidases. Biochem. Biophys. Res. Commun. 1991, 177:532-537.
157. Atsumi S., Iinuma H., Nosaka C., Umezawa K. Biological-activities of cyclophellitol. J. Antibiot. 1990, 43:1579-1585.
158. Atsumi S., Umezawa K., Iinuma H., Naganawa H., Nakamura H., Iitaka Y., Takeuchi T. Production, isolation and structure determination of a novel β-glucosidase inhibitor, cyclophellitol, from Phellinus sp. J. Antibiot. 1990, 43:49-53.
159. Gloster T.M., Madsen R., Davies G.J. Structural basis for cyclophellitol inhibition of a β-glucosidase. Org. Biomol. Chem. 2007, 5:444-446.
160. Atsumi S., Nosaka C., Ochi Y., Iinuma H., Umezawa K. Inhibition of experimental metastasis by an α-glucosidase inhibitor, 1,6-epi-cyclophellitol. Cancer Res. 1993, 53:4896-4899.
161. Tai V.W.F., Fung P.H., Wong Y.S., Shing T.K.M. Kinetic-studies on cyclophellitol analogs-Mechanism-based inactivators. Biochem. Biophys. Res. Commun. 1995, 213:175-180.
162. Legler G., Bause E. Epoxyalkyl oligo-(1→4)-β-d-glucosides as active-site-directed inhibitors of cellulases. Carbohydr. Res. 1973, 28:45-52.
163. Shulman M.L., Shiyan S.D., Khorlin A.Y. Specific irreversible inhibition of sweet-almond β-glucosidase by some β-glycopyranosylepoxyalkanes and β-d-glucopyranosyl isothiocyanate. Biochim. Biophys. Acta 1976, 445:169-181.
164. Eshdat Y., McKeIvy J.F., Sharon N. Identification of aspartic acid 52 as the point of an affinity label in hen egg lysozyme. J. Biol. Chem. 1973, 248:5892-5898.
165. Moult J., Eshdat Y., Sharon N. The identification by X-ray crystallography of the site of attachment of an affinity label to hen egg-white lysozyme. J. Mol. Biol. 1973, 75:1-4.
166. Eshdat Y., Dunn A., Sharon N. Chemical conversion of aspartic acid 52, a catalytic residue in hen egg-white lysozyme, to homoserine. Proc. Natl. Acad. Sci. U. S. A. 1974, 71:1658-1663.
167. 3H]-4,5-epoxypentyl β-cellobioside: Synthesis of inhibitor and stoichiometry of interaction. Carbohydr. Res. 1989, 188:245-250.
168. Hoj P.B., Condron R., Traeger J.C., McAuliffe J.C., Stone B.A. Identification of glutamic-acid 105 at the active-site of Bacillus amyloliquefaciens 1,3-1,4-β-d-glucan 4-glucanohydrolase using epoxide-based inhibitors. J. Biol. Chem. 1992, 267:25059-25066.
169. Hoj P.B., Rodriguez E.B., Iser J.R., Stick R.V., Stone B.A. Active site-directed inhibition by optically pure epoxyalkyl cellobiosides reveals differences in active-site geometry of two 1,3-1,4-β-d-glucan 4-glucanohydrolases-The importance of epoxide stereochemistry for enzyme inactivation. J. Biol. Chem. 1991, 266:11628-11631.
170. Keitel T., Simon O., Borriss R., Heinemann U. Molecular and active-site structure of a Bacillus 1,3-1,4-β-glucanase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5287-5291.
171. Macarron R., Vanbeeumen J., Henrissat B., Delamata I., Claeyssens M. Identification of an essential glutamate residue in the active-site of endoglucanase-III from Trichoderma reesei. FEBS Lett. 1993, 316:137-140.
172. Havukainen R., Torronen A., Laitinen T., Rouvinen J. Covalent binding of three epoxyalkyl xylosides to the active site of endo-1,4-xylanase II from Trichoderma reesei. Biochemistry 1996, 35:9617-9624.
173. Sulzenbacher G., Schulein M., Davies G.J. Structure of the endoglucanase I from Fusarium oxysporum: Native, cellobiose, and 3,4-epoxybutyl β-d-cellobioside-inhibited forms, at 2.3 Ångstrom resolution. Biochemistry 1997, 36:5902-5911.
174. Laitinen T., Rouvinen J., Perakyla M. Inversion of the roles of the nucleophile and acid/base catalysts in the covalent binding of epoxyalkyl xyloside inhibitor to the catalytic glutamates of endo-1,4-β-xylanase (XYNII): A molecular dynamics study. Protein Eng. 2000, 13:247-252.
175. Nakata M., Chong C., Nitawa Y., Toshima K., Tasuma K. A family of cyclophellitol analogs: Synthesis and evaluation. J. Antibiot. 1993, 46:1919-1924.
176. Caron G., Withers S.G. Conduritol aziridine: A new mechanism-based glucosidase inactivator. Biochem. Biophys. Res. Commun. 1989, 163:495-499.
177. Tong M.K., Ganem B. A potent new class of active-site-directed glycosidase inactivators. J. Am. Chem. Soc. 1988, 110:312-313.
178. Tatsuta K. Total synthesis and chemical design of useful glycosidase inhibitors. Pure Appl. Chem. 1996, 68:1341-1346.
179. Witte M.D., Kallemeijn W.W., Aten J., Li K.-Y., Strijland A., Donker-Koopman W.E., van den Nieuwendijk A.M., Bleijlevens B., Kramer G., Florea B.I., Hooibrink B., Hollak C.E., Ottenhoff R., Boot R.G., van der Marel G.A., Overkleeft H.S., Aerts J.M. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat. Chem. Biol. 2010, 6:907-913.
180. Witte M.D., Walvoort M.T., Li K.-Y., Kallemeijn W.W., Donker-Koopman W.E., Boot R.G., Aerts J.M., Codee J.D., van der Marel G.A., Overkleeft H.S. Activity-based profiling of retaining β-glucosidases: A comparative study. Chembiochem 2011, 12:1263-1269.
181. Kallemeijn W.W., Li K.-Y., Witte M.D., Marques A.R., Aten J., Scheij S., Jiang J., Willems L.I., Voorn-Brouwer T.M., van Roomen C.P.A.A., Ottenhoff R., Boot R.G., van den Elst H., Walvoort M.T.C., Florea B.I., Codee J.D., van der Marel G.A., Aerts J.M., Overkleeft H.S. Novel activity-based probes for broad-spectrum profiling of retaining β-exoglucosidases in situ and in vivo. Angew. Chem. Int. Ed. Engl. 2012, 51:12529-12533.
182. Ho M.W., O'Brien J.S., Radin N.S., Erickson J.S. Glucocerebrosidase: Reconstitution of activity from macromolecular components. Biochem. J. 1973, 131:173-176.
183. Pentchev P.G., Brady R.O., Hibbert S.R., Gal A.E., Shapiro D. Isolation and characterization of glucocerebrosidase from human placental tissue. J. Biol. Chem. 1973, 248:5256-5261.
184. Ho M.W. Identity of 'acid' β-glucosidase and glucocerebrosidase in human spleen. Biochem. J. 1973, 136:721-729.
185. Glew R.W., Christopher A.R., Schnure F.W., Lee R.E. The occurrence of β-glucocerebrosidase activity in the glucocerebroside-rich deposits of Gaucher's disease. Arch. Biochem. Biophys. 1974, 160:162-167.
186. Thudichum J.L.W. A Treatise on the Chemical Constitution of Brain 1884, Bailliere, Tindall, and Cox, London, United Kingdom.
187. Sonnino S., Prinetti A. Membrane domains and the "lipid raft" concept. Curr. Med. Chem. 2013, 20:4-21.
188. Chatterjee S., Sweeley C.C., Velicer L.F. Glycosphingolipids of human KB cells grown in monolayer, suspension, and synchronized cultures. J. Biol. Chem. 1975, 250:61-66.
189. Okazaki T., Bell R.M., Hannun Y.A. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J. Biol. Chem. 1989, 264:19076-19080.
190. Venable M.E., Lee J.Y., Smyth M.J., Bielawska A., Obeid L.M. Role of ceramide in cellular senescence. J. Biol. Chem. 1995, 270:30701-30708.
191. Hetz C.A., Hunn M., Rojas P., Torres V., Leyton L., Quest A.F. Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: Onset of necrosis is associated with delayed ceramide increase. J. Cell Sci. 2002, 115:4671-4683.
192. Adam D., Heinrich M., Kabelitz D., Schutze S. Ceramide: Does it matter for T cells?. Trends Immunol. 2002, 23:1-4.
193. Obeid L.M., Linardic C.M., Karolak L.A., Hannun Y.A. Programmed cell death induced by ceramide. Science 1993, 259:1769-1771.
194. Iwabuchi K., Yamamura S., Prinetti A., Handa K., Hakomori S.I. GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B16 cells. J. Biol. Chem. 1998, 273:9130-9138.
195. Zhang X., Kiechle F.L. Glycosphingolipids in health and disease. Ann. Clin. Lab. Sci. 2005, 34:3-13.
196. Liang Y.L., Ding Y., Levery S.B., Lobaton M., Handa K., Hakomori S.I. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4968-4973.
197. Beckham T.H., Cheng J.C., Marrison S.T., Norris J.S., Liu X. Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv. Cancer Res. 2013, 117:1-36.
198. Morad S.A., Cabot M.C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer 2013, 13:51-65.
199. Langeveld M., Aerts J.M. Glycosphingolipids and insulin resistance. Prog. Lipid Res. 2009, 48:126-205.
200. Samad F., Badeanlou L., Shah C., Yang G. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv. Exp. Med. Biol. 2011, 721:67-86.
201. Brice S.E., Cowart L.A. Sphingolipid metabolism and analysis in metabolic disease. Adv. Exp. Med. Biol. 2011, 721:1-17.
202. Neufeld E.F. Lysosomal storage diseases. Annu. Rev. Biochem. 1991, 60:257-280.
203. Aerts J.M., Hollak C., Boot R.G., Groener A. Biochemistry of glycosphingolipid storage disorders: Implications for therapeutic intervention. Philos. Trans. R. Soc. Lond. B 2003, 358. 10.1098/rstb.2003.
204. Ballabio A., Gieselmann V. Lysosomal disorders: From storage to cellular damage. Biochim. Biophys. Acta 2009, 1793:684-696.
205. Schulze H., Sandhoff K. Lysosomal lipid storage diseases. Cold Spring Harb. Perspect. Biol. 2011, 3:a004804.
206. Merrill A.H. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev. 2011, 111:6387-6422.
207. Quehenberger O., Armando A.M., Brown A.H., Milne S.B., Myers D.S., Merrill A.H., Bandyopadhyay S., Jones K.N., Kelly S., Shaner R.L., Sullards C.M., Wang E., Murphy R.C., Barkley R.M., Leiker T.J., Raetz C.R., Guan Z., Laird G.M., Six D.A., Russell D.W., McDonald J.G., Subramaniam S., Fahy E., Dennis E.A. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 2010, 51:3299-3305.
208. Wennekes T., van den Berg R.J., boot R.G., van der Marel G.A., Overkleeft H.S., Aerts J.M. Glycosphingolipids-Nature, function, and pharmacological modulation. Angew. Chem. Int. Ed. Engl. 2009, 48:8848-8869.
209. Lieb H. Cerebrosidspeicherung bei Splenomegalie, Typus Gaucher. Hoppe-Seylers Z. Physiol. Chem. 1923, 140:305-315.
210. Gaucher P.C.E. De l'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie 1882, Ph.D. thesis, Paris, France.
211. Aghion H. La maladie de Gaucher dans l'enfance 1993, Ph.D. Thesis, Paris, France.
212. Rosenberg A., Chargaff E. A re-investigation of the cerebroside deposited in Gaucher's disease. J. Biol. Chem. 1958, 233:1323-1326.
213. Agranoff B.W., Radin N., Suomi W. Enzymic oxidation of cerebrosides: Studies on Gaucher's disease. Biochim. Biophys. Acta 1962, 57:194-196.
214. Trams E.G., Brady R.O. Cerebroside synthesis in Gaucher's disease. J. Clin. Invest. 1960, 39:1546-1550.
215. Brady R.O., Kanfer J., Shapiro D. The metabolism of glucocerebrosides. Purification and properties of a glucocerebroside cleaving enzyme from spleen tissue. J. Biol. Chem. 1965, 240:39-43.
216. Brady R.O., Kanfer J.N., Shapiro D. Metabolism of glucocerebrosides. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun. 1965, 18:221-225.
217. Brady R.O., Kanfer J.N., Bradley P.M., Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 1966, 45:1112-1115.
218. Tsuji S., Choudary P.V., Martin B.M., Winfield S., Barranger J.A., Ginns E.I. Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase. J. Biol. Chem. 1986, 261:50-53.
219. Sorge J., West C., Westwood B., Beutler E. Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:7289-7293.
220. Reiner O., Wilder S., Givol D., Horowitz M. Efficient in vitro and in vivo expression of human glucocerebrosidase cDNA. DNA 1987, 6:101-108.
221. van Weely S., Brandsma M., Strijland A., Tager J.M., Aerts J.M. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta 1993, 1181:55-62.
222. Yildiz Y., Matern H., Thompson B., Allegood J.C., Warren R.L., Ramirez D.M., Hammer R.E., Hamra F.K., Matern S., Russell D.W. Mutation of β-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J. Clin. Invest. 2006, 116:2985-2994.
223. Boot R.G., Verhoek M., Donker-Koopman W., Strijland A., van Marle J., Overkleeft H.S., Wennekes T., Aerts J.M. Identification of the non-lysosomal glucosylceramidase as β-glucosidase 2. J. Biol. Chem. 2007, 282:1305-1312.
224. Skovbjerg H., Sjöström H., Norén O. Purification and characterisation of amphiphilic lactase/phlorizin hydrolase from human small intestine. Eur. J. Biochem. 1981, 114:653-661.
225. Wacker H., Keller P., Falchetto R., Legler G., Semenza G. Location of the two catalytic sites in intestinal lactase-phlorizin hydrolase. Comparison with sucrase-isomaltase and with other glycosidases, the membrane anchor of lactase-phlorizin hydrolase. J. Biol. Chem. 1992, 267:18744-18752.
226. Gopalan V., Pastuszyn A., Galey W.R., Glew R.H. Exolytic hydrolysis of toxic plant glucosides by guinea pig liver cytosolic β-glucosidase. J. Biol. Chem. 1992, 267:14027-14032.
227. Yahata K., Mori K., Arai H., Koide S., Ogawa Y., Mukoyama M., Sugawara A., Ozaki S., Tanaka I., Nabeshima Y., Nakao K. Molecular cloning and expression of a novel klotho-related protein. J. Mol. Med. (Berl.) 2000, 78:389-394.
228. Mistry P.K., Liu J., Yang M., Nottoli T., McGrath J., Jain D., Zhang K., Keutzer J., Chuang W.L., Mehal W.Z., Zhao H., Lin A., Mane S., Liu X., Peng Y.Z., Li J.H., Agrawal M., Zhu L.L., Blair H.C., Robinson L.J., Iqbal J., Sun L., Zaidi M. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19473-19478.
229. Gaspar P., Kallemeijn W.W., Strijland A., Scheij S., Van Eijk M., Aten J., Overkleeft H.S., Balreira A., Zunke F., Schwake M., Sá Miranda C., Aerts J.M. Action myoclonus-renal failure syndrome: Diagnostic applications of activity-based probes and lipid analysis. J. Lipid Res. 2014, 55:138-145.
230. Jak M., van Bochove G.G., Reits E.A., Kallemeijn W.W., Tromp J.M., Umana P., Klein C., van Lier R.A., van Oers M.H., Eldering E. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood 2011, 118:5178-5188.
231. Johnsson L.M., Murray G.J., Sorrell S.H., Strijland A., Aerts J.F., Ginns E.I., Barranger J.A., Tager J.M., Schram A.W. Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur. J. Biochem. 1987, 164:171-179.
232. Aerts J.M., Brul S., Donker-Koopman W.E., van Weely S., Murray G.J., Barranger J.A., Tager J.M., Schram A.W. Efficient routing of glucocerebrosidase to lysosomes requires complex oligosaccharide chain formation. Biochem. Biophys. Res. Commun. 1986, 141:452-458.
233. Aerts J.M., Schram A.W., Strijland A., van Weely S., Jonsson L.M., Tager J.M., Sorrell S.H., Ginns E.I., Barranger J.A., Murray G.J. Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. Biochim. Biophys. Acta 1988, 964:303-308.
234. Aerts J.M., Heikoop J., van Weely S., Donker-Koopman W.E., Barranger J.A., Tager J.M., Schram A.W. Characterization of glucocerebrosidase in peripheral blood cells and cultured blastoid cells. Exp. Cell Res. 1988, 177:391-398.
235. Van Weely S., Aerts J.M., Van Leeuwen M.B., Heikoop J.C., Donker-Koopman W.E., Barranger J.A., Tager J.M., Schram A.W. Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase. Eur. J. Biochem. 1990, 191:669-677.
236. Tybulewicz V.L., Tremblay M.L., LaMarca M.E., Willemsen R., Stubblefield B.K., Winfield S., Zablocka B., Sidransky E., Martin B.M., Huang S.P., Mintzer K.A., Westphal H., Mulligan R.C., Ginnis E.I. Animal-model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 1992, 357:407-410.
237. Liu Y., Suzuki K., Reed J.D., Grinberg A., Westphal H., Hoffmann A., Doring T., Sandhoff K., Proia R.L. Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure (SIMP). Proc. Natl. Acad. Sci. U. S. A. 1998, 95:2503-2508.
238. Beutler E., West C., Torbett B.E., Deguchi H. A chimeric mouse model of Gaucher disease. Mol. Med. 2002, 8:247-250.
239. Mizukami H., Mi Y., Wada R., Kono M., Yamashita T., Liu Y., Werth N., Sandhoff R., Sandhoff K., Proia R.L. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J. Clin. Invest. 2002, 109:1215-1221.
240. Xu Y.H., Quinn B., Witte D., Grabowski G.A. Viable mouse models of acid β-glucosidase deficiency-The defect in Gaucher disease. Am. J. Pathol. 2003, 163:2093-2101.
241. Sun Y., Quinn B., Witte D.P., Grabowski G.A. Gaucher disease mouse models: Point mutations at the acid β-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J. Lipid Res. 2005, 46:2102-2113.
242. Sinclair G.B., Jevon G., Colobong K.E., Randall D.R., Choy F.Y., Clarke L.A. Generation of a conditional knockout of murine glucocerebrosidase: Utility for the study of Gaucher disease. Mol. Genet. Metab. 2007, 90:148-156.
243. Enquist I.B., Lo Bianco C., Ooka A., Nilsson E., Mansson J.E., Ehinger M., Richter J., Brady R.O., Kirik D., Karlsson S. Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17483-17488.
244. Sanders A., Hemmelgarn H., Melrose H.L., Hein L., Fuller M., Clarke L.A. Transgenic mice expressing human glucocerebrosidase variants: Utility for the study of Gaucher disease. Blood Cells Mol. Dis. 2013, 51:109-115.
245. Atsumi S., Nosaka C., Iinuma H., Umezawa K. Inhibition of glucocerebrosidase and induction of neural abnormality by cyclophellitol in mice. Arch. Biochem. Biophys. 1992, 297:362-367.
246. Atsumi S., Nosaka C., Iinuma H., Umezawa K. Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol. Arch. Biochem. Biophys. 1993, 304:302-304.
247. Das P.K., Murray G.J., Gal A.E., Barranger J.A. Glucocerebrosidase deficiency and lysosomal storage of glucocerebroside induced in cultured macrophages. Exp. Cell Res. 1987, 168:463-474.
248. Schueler U.H., Kolter T., Kaneski C.R., Zirzow G.C., Sandhoff K., Brady R.O. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J. Inherit. Metab. Dis. 2004, 27:649-658.
249. Kanfer J.N., Legler G., Sullivan J., Raghavan S.S., Mumford R.A. Gaucher mouse. Biochem. Biophys. Res. Commun. 1975, 67:85-90.
250. Kanfer J.N., Stephens M.C., Singh H., Legler G. The Gaucher mouse. Prog. Clin. Biol. Res. 1982, 95:627-644.
251. Beutler E. Gaucher disease. Blood Rev. 1988, 2:59-70.
252. Morales L.E. Gaucher's disease: A review. Ann. Pharmacother. 1996, 30:381-388.
253. Cox T.M., Schofield J.P. Gaucher's disease: Clinical features and natural history. Baillieres Clin. Haematol. 1997, 10:657-689.
254. Ihler G.M., Glew R.H., Schnure F.W. Enzyme loading of erythrocytes. Proc. Natl. Acad. Sci. U. S. A. 1973, 70:2663-2666.
255. Brady R.O., Pentchev P.G., Gal A.G. Investigations in enzyme replacement therapy in lipid storage diseases. Fed. Proc. 1975, 34:1310-1315.
256. Brady R.O., Pentchev P.G., Gal A.E., Hibbert S.R., Dekaban A.S. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N. Engl. J. Med. 1974, 291:989-993.
257. Ezekowitz R.A.B., Stahl P.D. The structure and function of vertebrate mannose lectin-like proteins. J. Cell Sci. 1989, 9:121-133.
258. Wileman T.E., Lennartz M.R., Stahl P.D. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2501-2505.
259. Lennartz M.R., Cole F.S., Shepherd V.L., Wileman T.E., Stahl P.D. Isolation and characterization of a mannose-specific endocytosis receptor from human placenta. J. Biol. Chem. 1987, 262:9942-9944.
260. Magnusson S., Berg T. Extremely rapid endocytosis mediated by the mannose receptor of sinusoidal endothelial rat liver cells. Biochem. J. 1989, 257:651-656.
261. Stang E., Kindberg G.M., Berg T., Roos N. Endocytosis mediated by the mannose receptor in liver endothelial cells. An immunocytochemical study. Eur. J. Cell Biol. 1991, 52:67-76.
262. Takahashi K., Donovan M.J., Rogers R.A., Ezekowitz R.A. Distribution of murine mannose receptor expression from early embryogenesis through to adulthood. Cell Tissue Res. 1998, 292:311-323.
263. Doebber T.W., Wu M.S., Bugianesi R.L., Ponpipom M.M., Furbish F.S., Barranger J.A., Brady R.O., Shen T.Y. Enhanced macrophage uptake of synthetically glycosylated human placental β-glucocerebrosidase. J. Biol. Chem. 1982, 257:2193-2199.
264. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E., Grewall R.P., Yu K.-T. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 1991, 324:1464-1470.
265. Brumshtein B., Salinas P., Peterson B., Chan V., Silman I., Sussman J.L., Savickas P.J., Robinson G.S., Futerman A.H. Characterization of gene-activated human acid-β-glucosidase: Crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010, 20:24-32.
266. Aviezer D., Brill-Almon E., Shaaltiel Y., Hashmueli S., Bartfeld D., Mizrachi S., Liberman Y., Freeman A., Zimran A., Galun E. A plant-derived recombinant human glucocerebrosidase enzyme-A preclinical and phase I investigation. PLoS One 2009, 4:e4792.
267. Zimran A., Elstein D., Levy-Lahad E., Zevin S., Hadas-Halpern I., Bar-Ziv Y., Foldes J., Schwartz A.J., Abrahamov A. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995, 345:1479-1480.
268. Grabowski G.A., Leslie N., Wenstrup R. Enzyme therapy for Gaucher disease: The first 5 years. Blood Rev. 1998, 12:115-133.
269. Tekoah Y., Tzaban S., Kizhner T., Hainrichson M., Gantman A., Golembo M., Aviezer D., Shaaltiel Y. Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Biosci. Rep. 2013, 33. 10.1042/BSR20130081.
270. Berger J., Stirnemann J., Bourgne C., Pereira B., Pigeon P., Heraoui D., Froissart R., Rapatel C., Rose C., Belmatoug N., Berger M.G. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable. Br. J. Haematol. 2012, 157:274-277.
271. Xu Y.H., Sun Y., Barnes S., Grabowski G.A. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One 2010, 5:e10750.
272. Van Patten S.M., Hughes H., Huff M.R., Piepenhagen P.A., Waire J., Qiu H., Ganesa C., Reczek D., Ward P.V., Kutzko J.P., Edmunds T. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 2007, 17:467-478.
273. Piepenhagen P.A., Vanpatten S., Hughes H., Waire J., Murray J., Andrews L., Edmunds T., O'Callaghan M., Thurberg B.L. Use of direct fluorescence labeling and confocal microscopy to determine the biodistribution of two protein therapeutics, Cerezyme and Ceredase. Microsc. Res. Tech. 2010, 73:694-703.
274. Yatziv S., Newburg D.S., Livni N., Barfi G., Kolodny E.H. Gaucher-like changes in human-blood derived macrophages induced by b-glucocerebrosidase inhibition. J. Lab. Clin. Med. 1988, 111:416-420.